Acrux half-year financial report - December 2015
Released
Released
Announcement PDF
ACRUX LIMITED
ABN: 72 082 001 152
AND CONTROLLED ENTITIES
FINANCIAL REPORT
FOR THE HALF-YEAR ENDED
31 DECEMBER 2015
This half-year financial report is to be read in conjunction
with the financial report for the year ended 30 June 2015
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
FINANCIAL REPORT FOR THE HALF-YEAR ENDED
31 DECEMBER 2015
TABLE OF CONTENTS
Directors’ Report
2
Auditor’s Independence Declaration
6
Financial Report for the half year ended 31 December 2015
Condensed Consolidated Statement of Profit or Loss and Other
Comprehensive Income
7
Condensed Consolidated Statement of Financial Position
9
Condensed Consolidated Statement of Changes in Equity
10
Condensed Consolidated Statement of Cash Flows
11
Notes to the Condensed Consolidated Financial Statements
12
Directors’ Declaration
16
Independent Auditor’s Review Report
17
1
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
DIRECTORS’ REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2015
The Directors present their report together with the condensed financial report of the consolidated
entity consisting of Acrux Limited (the Company) and its controlled entities (the Group), for the
half-year ended 31 December 2015 and independent review report thereon. This financial report
has been prepared in accordance with AASB 134 Interim Financial Reporting.
Directors’ names
The names of the Directors in office at any time during or since the end of the half-year are:
Name
Period of Directorship
R Dobinson (Chairman)
Director since 19 March 1998
B Parncutt
Director since 30 April 2012
T Oldham
Director since 1 October 2013
M Kotsanis
Director since 3 November 2014
The Directors have been in office since the start of the financial period to the date of this report
unless otherwise stated.
Review of operations
The consolidated profit of the Group for the half-year after providing for income tax amounted to
$9.7 million (2014: $7.0 million), equating to earnings of $0.06 cents per share (2014: $0.04 cents
per share).
During the period, the Company communicated its growth strategy, providing clarity and direction
on its framework for value creation. Income diversification will be derived through the
development of three distinct therapy portfolios:
Marketed topical portfolio. The marketed topical portfolio includes the Company’s commercialised
products, Axiron® (testosterone), Evamist® (estradiol) and Lenzetto® (estradiol).
Axiron global sales by our partner Eli Lilly and Company over the six months ended 31 December
2015 were US$83.0M compared to US$83.9M over the same period last year. Axiron’s US volume
market share remained steady, ending the period at 14.4%(1). Generic alternatives exist for
Androgel 1% (an alternative testosterone replacement therapy) and were introduced from January
2015, however these generics are not substitutable for Axiron and as a result have not impacted
market share to date.
(1)
Source: IMS data
2
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
Since the release of the Food and Drug Administration (FDA) communication in March 2015,
manufacturers of approved testosterone replacement therapy products in the United States have
been in dialogue with the FDA “to conduct a well-designed clinical trial”.
During the half-year, marketing approval was received for Lenzetto in multiple European countries.
Lenzetto has now been launched in Poland, the Czech Republic and Hungary, by our partner
Gedeon Richter. A sequential launch in additional European countries will occur over the following
months.
Specialty topical portfolio. Onychomycosis is the Company’s lead specialty topical program,
targeting fungal infection of the nail bed in toes and fingers. Development efforts have progressed
with a number of formulations delivering excellent nail penetration. The Company has assessed
the intellectual property landscape and has a clear path with which to move forward.
Generic topical portfolio. The Company’s generic topical portfolio is progressing to plan with three
products scoped and development commenced. Activities on a fourth product will commence
during the quarter ended March 2016. It is expected the first commercial events for the portfolio
will occur during the 2019 calendar year. Details of product candidates are withheld by Acrux for
competitive reasons.
The Company has taken a diligent and active approach to portfolio management, assessing a
number of opportunities over the period. Our resources are dedicated to executing our lead
Onychomycosis project and making progress on 4 candidates within our generic portfolio.
The consolidated entity’s profit before tax for the half-year improved 29.1% to $13.3 million (2014:
$10.3 million). The consolidated entity’s profit after tax improved 38.9% to $9.7 million (2014: $7.0
million) with a tax expense of $3.6 million (2014: $3.3 million).
Revenue
Revenue for the half-year increased $3.8 million or 26.6% to $18.0 million (2014: $14.2 million).
Royalty revenue from Axiron increased $1.5 million to $15.2 million (2014: $13.7 million). During
the 6 months ended 31 December 2015, a milestone of US$2M was received from Gedeon Richter
(2014: Nil). Interest on cash deposits were $0.2 million (2013: $0.3 million).
3
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
Operating Expenses
Total operating expenditure for the half-year increased to $4.7 million (2014: $3.9 million). Royalty
payments due to Monash Investment Trust increased to $0.6 million (2014: $0.5 million), in-line
with product income. Employee benefits increased to $1.7 million (2015: $1.3 million), partially
offset by a reduction in Director’s fees (2015: $0.1 million, 2014: $0.2 million). The net increase
represents investment in research and development, associated with the Company’s growth
strategy. Share option expense was $0.2 million (2015: $nil) and reflects timing of costs associated
with the CEO Share Option Plan. Remaining costs totalled $2.1 million (2014: $1.9 million), the
increase associated with obtaining market data to assist in identification and commercialisation of
the generic topical portfolio.
Income Tax
Income tax expense of $3.6 million (2014: $3.3 million) was recorded for the reporting period.
Further details of the income tax expense are provided at Note 2 of the financial report.
Cash flow
Gross cash received was primarily from the receipt of royalties and milestones for the half-year
ended December 2015 was $14.9 million (2014: $11.4 million). The Company paid income tax of
$2.6 million (2014: $5.3 million) and paid $3.9 million to suppliers and employees (2014: $2.9
million).
Capital was returned to shareholders via payment of the 2015 final dividend, totalling $9.9 million
(6 cents per share).
Cash reserves at the end of the period were $21.5 million (31 December 2014: $15.8 million).
Contributed Equity
There were no changes to contributed equity during the reporting period.
The number of outstanding employee share options on issue at the end of the reporting period was
4,380,000 (30 June 2015: 3,380,000), representing 2.6% of the issued share capital. Share Options
were issued under the Employee Share Plan in January 2016. Refer “After balance date events”
below for further details.
Significant changes in the state of affairs
There have been no significant changes in the consolidated group’s state of affairs during and since
the end of the reporting period.
4
&
ri'!k
ACRuX
DRUGDE+lVERYSOLlmONS
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
After balance date events
The Company operates an Employee Share Option Plan (ESOP) which was approved by members
on 17 November 2015. On 25 January, employees accepted 774,000 0ptions offered by the Board
under this Plan. The strike price of these Options is 50.82 per Share Option. Options hold no
participation rights, but shares issued on exercise of options rank equally with existing shares.
Options will vest on 25 January 2017, subject to performance hurdles being achieved.
Rounding of amounts to nearest thousand dollars
The amounts contained in the Report and in the Financial Report have been rounded to the nearest
thousand dollars (where rounding is applicable) under the option available to the Company under
ASIC Class Order 98/0100. The Company is an entity to which the Class Order applies.
Signed in accordance with a resolution of the Directors:
x2! ,',?.
Dire cto r.. . aaa aaa aaa ... .., ., ,l,,, ,,,,,,,, , , ,-,,,',,, :,,, ,,,-,,, ,?:,,, , ,,, ,-,',,,, '-,,,, , ,,,,, , ,,,,, , ,,, ,,, ,,,,, , ,,,,,, ,,,,,, ,,,
Dated tnis 24fh day of February 2016
s
ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES
AUDITOR’S INDEPENDENCE DECLARATION
TO THE DIRECTORS OF ACRUX LIMITED
In relation to the independent auditor’s review for the half‐year ended 31 December 2015, to the best of
my knowledge and belief there have been:
(i)
No contraventions of the auditor independence requirements of the Corporations Act 2001; and
(ii)
No contraventions of any applicable code of professional conduct.
This declaration is in respect of Acrux Limited and the entities it controlled during the period.
S SCHONBERG
Partner
PITCHER PARTNERS
Melbourne
Dated 24 February 2016
6
An independent Victorian Partnership ABN 27 975 255 196
Level 19, 15 William Street, Melbourne VIC 3000
Liability limited by a scheme approved under Professional Standards Legislation
Pitcher Partners is an association of independent firms
Melbourne | Sydney | Perth | Adelaide | Brisbane| Newcastle
An independent member of Baker Tilly International
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
CONDENSED CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2015
Half-year
31 Dec
31 Dec
2015
2014
$’000
$’000
Revenue and Other Income
Royalty Revenue
Milestone Revenue
Interest income
Other income
Less: Expenses
Employee benefits expense
Directors’ fees
Share options expense
Depreciation and amortisation expenses
Occupancy expenses
External research and development expenses
Professional fees
Royalty expense
Other expenses
Profit before income tax expense
Income tax expense
Net profit from continuing operations
Total comprehensive income for the half-year
15,224
2,534
242
4
18,004
13,729
313
176
14,218
1,716
136
226
717
224
398
240
631
412
4,700
1,298
241
713
206
393
357
486
239
3,934
13,304
3,558
9,746
9,746
10,284
3,266
7,018
7,018
The accompanying notes form part of these condensed financial statements
7
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
CONDENSED CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(Continued)
FOR THE HALF-YEAR ENDED 31 DECEMBER 2015
Half-year
31 Dec
31 Dec
2015
2014
$’000
$’000
Total comprehensive income attributable to members of the parent arises from:
Continuing operations
Discontinued operations
9,746
9,746
7,018
7,018
Earnings per share for profit attributable to the equity holders of the parent entity:
Basic earnings per share
Diluted earnings per share
$0.06
$0.06
The accompanying notes form part of these condensed financial statements
8
$0.04
$0.04
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
CONDENSED CONSOLIDATED
STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2015
31 Dec
2015
$’000
30 June
2015
$’000
Current assets
Cash and cash equivalents
Receivables
Total current assets
21,539
8,318
29,857
23,068
4,943
28,011
Non-current assets
Plant and equipment
Intangible assets
Total non-current assets
Total assets
143
19,705
19,848
49,705
92
20,392
20,484
48,495
Current liabilities
Payables
Current tax payable
Provisions
Total current liabilities
1,458
3,327
275
5,060
1,150
1,764
288
3,202
Non-current liabilities
Provisions
Deferred tax liabilities
Total non-current liabilities
Total liabilities
Net assets
16
4,024
4,040
9,100
40,605
19
4,649
4,668
7,870
40,625
Equity
Contributed capital
Reserves
Retained earnings
Equity attributable to owners of Acrux Limited
Total equity
95,873
1,420
(56,688)
40,605
40,605
95,873
1,194
(56,442)
40,625
40,625
The accompanying notes form part of these condensed financial statements
9
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
CONDENSED CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2015
Consolidated
Contributed
equity
Reserves
$’000
$’000
Balance as at 1 July 2014
Profit for the half-year as reported in 2014
financial statements
Total comprehensive income for the half-year
Transactions with owners in their capacity as
owners:
Employee share scheme
Dividends paid
Balance as at 31 December 2014
Balance as at 1 July 2015
Profit for the half-year as reported in 2015
financial statements
Total comprehensive income for the half-year
Retained
earnings
$’000
95,873
638
(54,454)
42,057
-
-
7,018
7,018
-
-
7,018
7,018
95,873
638
(13,322)
(13,322)
(60,758)
(13,322)
(13,322)
35,753
95,873
1,194
(56,442)
40,625
-
9,746
9,746
-
9,746
9,746
(9,992)
(9,992)
(56,688)
226
(9,992)
(9,766)
40,605
-
Transactions with owners in their capacity as
owners:
Employee share scheme
Dividends paid
226
Balance as at 31 December 2015
95,873
226
1,420
The accompanying notes form part of these condensed financial statements
10
Total
Equity
$’000
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
CONDENSED CONSOLIDATED
STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2015
Half-year
31 Dec
31 Dec
2015
2014
$’000
$’000
Cash flow from operating activities
Receipts from product agreements and government
Payments to suppliers and employees
Interest received
Income tax paid
Net cash provided by operating activities
14,657
(3,873)
206
(2,619)
8,371
11,080
(2,947)
368
(5,271)
3,230
(54)
(54)
(13)
(13)
Cash flow from financing activities
Dividends paid
Net cash used in financing activities
(9,894)
(9,894)
(13,244)
(13,244)
Net decrease in cash and cash equivalents
Foreign exchange differences on cash holdings
Cash and cash equivalents at beginning of half-year
Cash and cash equivalents at end of the half-year
(1,577)
48
23,068
21,539
(10,027)
44
25,775
15,792
Cash flow from investing activities
Payment for property, plant and equipment
Net cash used in investing activities
The accompanying notes form part of these condensed financial statements
11
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
HALF-YEAR 31 DECEMBER 2015
NOTE 1: BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL REPORT
This condensed consolidated half-year financial report does not include all the notes of the
type usually included in an annual financial report.
It is recommended that this half-year financial report be read in conjunction with the annual
financial report for the year ended 30 June 2015 and any public announcements made by
Acrux Limited during the half-year in accordance with any continuous disclosure obligations
arising under the Corporations Act 2001.
Acrux Limited is a for-profit entity for the purpose of preparing the financial statements.
The half-year financial report was authorised for issue by the Directors on 24 February 2016.
(a)
Basis of preparation
This condensed consolidated half-year financial report has been prepared in accordance with
Australian Accounting Standard AASB 134 Interim Financial Reporting, as appropriate for forprofit entities, and the Corporations Act 2001. Compliance with AASB 134, as appropriate for
for-profit entities, ensures compliance with International Financial Reporting Standard IAS 34
Interim Financial Reporting.
The half-year financial report has been prepared under the historical cost convention, as
modified by revaluations to fair value for certain classes of assets as described in the
accounting policies.
The accounting policies applied in this half-year financial report are consistent with those of
the annual financial report for the year ended 30 June 2015 and the corresponding half-year
except as described below in Note 1(b).
(b)
Summary of the significant accounting policies
A number of new or amended accounting standards become applicable for the current
reporting period, however, the group did not have to change its accounting policies or make
retrospective adjustments as a result of adopting these standards. There will be some
changes to the disclosures in the 30 June 2016 annual report as a consequence of these
amendments. The fair value of financial assets and financial liabilities approximate their
carrying amounts as disclosed in the condensed consolidated statement of financial position.
The accompanying notes form part of these financial statements
12
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
NOTE 1: BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL REPORT (continued)
(c)
Rounding amounts
The Company is of a kind referred to in ASIC Class Order CO 98/0100 and in accordance
with that Class Order, amounts in the financial statements have been rounded off to the
nearest thousand dollars, or in certain cases, to the nearest dollar.
NOTE 2: INCOME TAX
The parent entity, Acrux Limited is a Pooled Development Fund (PDF):
PDFs are taxed at 15% on income and gains from investments in small to
medium enterprises;
PDFs are taxed at 25% on other income;
Groups containing a PDF are not permitted to consolidate for tax purposes.
The investee companies of a PDF are subject to the general corporate company
tax rate of 30%.
The consolidated entities tax rate for the 6 months ended 31 December 2015 is 26.7% and
differs to the general corporate company tax rate of 30% primarily due to nil tax
expense/liability on one of the profit making investee companies which has previous
unrecognised tax losses.
NOTE 3: DIVIDENDS
Half-year
31 Dec
31 Dec
2015
2014
$’000
$’000
(a)
Dividends paid or declared
Dividends paid at 6 cents per share fully franked at 30% (2014:
8 cents per share, fully franked)
9,992
The accompanying notes form part of these condensed financial statements
13
13,322
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
NOTE 4: SEGMENT INFORMATION
The consolidated entity operates as a single operating segment. Internal management
reporting systems present financial information as a single segment. The segment derives its
revenue from developing and commercialising products using unique technology.
Additional information on revenue:
Half-year
31 Dec
31 Dec
2015
2014
$’000
$’000
Product/Service
Axiron
Other revenue
Total revenue
15,179
2,825
18,004
13,674
544
14,218
Country of Origin
Australia
Switzerland 1
Other
Total revenue
242
15,179
2,583
18,004
336
13,674
208
14,218
All assets are located in Australia.
1
Axiron revenue is receivable from a Swiss subsidiary of Eli Lilly and Company
The accompanying notes form part of these condensed financial statements
14
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
NOTE 5: CONTINGENT LIABILITIES
There were no contingent liabilities as at 31 December 2015.
NOTE 6: SUBSEQUENT EVENTS
Employees accepted 774,000 Options issued by the Board pursuant to the terms of the
Employee Share Option Plan (ESOP), which was approved at the Acrux Limited Annual
General Meeting on 17 November 2015. The strike price of these Options is $0.82 cents
per Share Option. Options hold no participation rights, but shares issued on exercise of
options rank equally with existing shares. Options will vest on 23 January 2017, subject to
performance hurdles being achieved.
There has been no other matter or circumstance which has arisen since 31 December 2015
that has significantly affected or may significantly affect:
a) the operations, in financial periods subsequent to 31 December 2015, of the
consolidated entity, or
b) the results of those operations, or
c) the state of affairs, in financial periods subsequent to 31 December 2015, of the
consolidated entity.
The accompanying notes form part of these condensed financial statements
15
&
t'!k
ACRUX
DRUGDEUVERYS(MRlnONS
ACRUX LIMITED AND CONTROLLED ENTITIES
ABN: 72 082 001 152
DIRECTORS' DECLARATION
The Directors declare that the financial statements and notes set out on pages 7 to 16 in
accordance with the Corporations Act 2001 :
*
Comply with Australian Accounting Standard AASB 134 Interim Financial Reporting
and the Corporations Regulations 2001, and other mandatory professional reporting
requirements; and
*
Give a true and fair view of the financial position of the consolidated entity as at 31
December 2015 and of its performance for the half-year ended on that date.
In the Directors' opinion there are reasonable grounds to believe that Acrux Limited will be
able to pay its debts as and when they become due and payable.
This declaration is made in accordance with a resolution of the Directors.
iL
I
'%-
Ross Dobinson
Non-Executive Chairman
Melbourne
Date
'Th
=/'/ i&
The accompanying notes form part of these condensed financial statements
16
ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES
INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
ACRUX LIMITED
We have reviewed the accompanying half‐year financial report of Acrux Limited and controlled entities,
which comprises the condensed consolidated statement of financial position as at 31 December 2015, the
condensed consolidated statement of comprehensive income, condensed consolidated statement of
changes in equity and condensed consolidated statement of cash flows for the half‐year ended on that date,
notes comprising a summary of significant accounting policies and other explanatory information, and the
directors’ declaration of the consolidated entity comprising the company and the entities it controlled at the
period’s end or from time to time during the half year.
Directors’ Responsibility for the Half‐Year Financial Report
The directors of the company are responsible for the preparation of the half‐year financial report that gives
a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and
for such internal control as the directors determine is necessary to enable the preparation of the half‐year
financial report that gives a true and fair view and is free from material misstatement, whether due to fraud
or error.
Auditor's Responsibility
Our responsibility is to express a conclusion on the half‐year financial report based on our review. We
conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a
Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis
of the procedures described, we have become aware of any matter that makes us believe that the half‐year
financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of
the consolidated entity's financial position as at 31 December 2015 and its performance for the half‐year
ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the
Corporations Regulations 2001. As the auditor of Acrux Limited, ASRE 2410 requires that we comply with the
ethical requirements relevant to the audit of the annual financial report.
A review of a half‐year financial report consists of making enquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other review procedures. A review is
substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and
consequently does not enable us to obtain assurance that we would become aware of all significant matters
that might be identified in an audit. Accordingly, we do not express an audit opinion.
Independence
In conducting our review, we have complied with the independence requirements of the Corporations Act
2001.
17
An independent Victorian Partnership ABN 27 975 255 196
Level 19, 15 William Street, Melbourne VIC 3000
Liability limited by a scheme approved under Professional Standards Legislation
Pitcher Partners is an association of independent firms
Melbourne | Sydney | Perth | Adelaide | Brisbane| Newcastle
An independent member of Baker Tilly International
ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES
INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
ACRUX LIMITED
Conclusion
Based on our review, which is not an audit, we have not become aware of any matter that makes us believe
that the half‐year financial report of Acrux Limited is not in accordance with the Corporations Act 2001,
including:
(a)
giving a true and fair view of the consolidated entity's financial position as at 31 December 2015 and
of its performance for the half‐year ended on that date; and
(b)
complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations
Regulations 2001.
S SCHONBERG
Partner
PITCHER PARTNERS
Melbourne
Dated 24 February 2016
18
An independent Victorian Partnership ABN 27 975 255 196
Level 19, 15 William Street, Melbourne VIC 3000
Liability limited by a scheme approved under Professional Standards Legislation
Pitcher Partners is an association of independent firms
Melbourne | Sydney | Perth | Adelaide | Brisbane| Newcastle
An independent member of Baker Tilly International
Share your feedback
Discover